Advantages of switching to elvitegravir/cobicistat/emtricitabine/tenofovir therapy in virologically-suppressed people living with human immunodeficiency virus/acquired immune deficiency syndrome

Ethical approval was obtained from the Human Medical Ethics Committee of Tianjin Second People's Hospital (No. There was no significant change in the median aspartate transaminase concentration over the 12-month follow-up period after switching. Acknowledgments We acknowledge the HIV health care providers for their diagnosis, nursing, and treatment of HIV/AIDS patients in Tianjin Second People's Hospital. The funders played no role in study design, data collection and analysis, the decision to publish, or preparation of the manuscript.